Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. The post Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow appeared first on Investor's Business Daily.
Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.
The post Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
